JP2024529068A - スルファミド誘導体、その調製方法及びその医薬的使用 - Google Patents

スルファミド誘導体、その調製方法及びその医薬的使用 Download PDF

Info

Publication number
JP2024529068A
JP2024529068A JP2024507166A JP2024507166A JP2024529068A JP 2024529068 A JP2024529068 A JP 2024529068A JP 2024507166 A JP2024507166 A JP 2024507166A JP 2024507166 A JP2024507166 A JP 2024507166A JP 2024529068 A JP2024529068 A JP 2024529068A
Authority
JP
Japan
Prior art keywords
group
general formula
cancer
salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024507166A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024529068A5 (enExample
Inventor
暁敏 張
偉民 胡
峰 賀
維康 陶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Shanghai Hengrui Pharmaceutical Co Ltd
Publication of JP2024529068A publication Critical patent/JP2024529068A/ja
Publication of JP2024529068A5 publication Critical patent/JP2024529068A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024507166A 2021-08-10 2022-08-10 スルファミド誘導体、その調製方法及びその医薬的使用 Pending JP2024529068A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202110913249 2021-08-10
CN202110913249.1 2021-08-10
CN202111142090.4 2021-09-28
CN202111142090 2021-09-28
CN202111500231 2021-12-09
CN202111500231.5 2021-12-09
PCT/CN2022/111395 WO2023016484A1 (zh) 2021-08-10 2022-08-10 磺酰胺衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
JP2024529068A true JP2024529068A (ja) 2024-08-01
JP2024529068A5 JP2024529068A5 (enExample) 2025-08-19

Family

ID=85200573

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024507166A Pending JP2024529068A (ja) 2021-08-10 2022-08-10 スルファミド誘導体、その調製方法及びその医薬的使用

Country Status (10)

Country Link
US (1) US20250145637A1 (enExample)
EP (1) EP4385989A4 (enExample)
JP (1) JP2024529068A (enExample)
KR (1) KR20240046530A (enExample)
CN (1) CN117597341A (enExample)
AU (1) AU2022325367A1 (enExample)
CA (1) CA3228411A1 (enExample)
MX (1) MX2024001777A (enExample)
TW (1) TW202321263A (enExample)
WO (1) WO2023016484A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023088233A1 (en) 2021-11-16 2023-05-25 Insilico Medicine Ip Limited Lysine acetyltransferase 6a (kat6a) inhibitors and uses thereof
CA3241874A1 (en) * 2021-12-13 2023-06-22 Aurigene Oncology Limited Fused benzoisoxazolyl compounds as kat6a inhibitors
CN116621859A (zh) * 2022-02-18 2023-08-22 山东轩竹医药科技有限公司 三并环类kat6抑制剂
AU2023241822A1 (en) 2022-03-28 2024-09-26 Isosterix, Inc. Inhibitors of the myst family of lysine acetyl transferases
AU2024217108A1 (en) * 2023-02-10 2025-09-18 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Crystalline form of sulfonamide derivative and preparation method therefor
CN120917003A (zh) 2023-03-16 2025-11-07 奥列马制药公司 酰基磺酰胺kat6a抑制剂
WO2024201334A1 (en) * 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof
WO2025007873A1 (zh) 2023-07-04 2025-01-09 上海齐鲁制药研究中心有限公司 Kat6抑制剂
WO2025098417A1 (zh) * 2023-11-08 2025-05-15 再和医药科技（苏州）有限公司 磺酰胺类化合物及其应用
US20250161289A1 (en) * 2023-11-10 2025-05-22 Prelude Therapeutics Incorporated KAT6 Targeting Compounds
WO2025136811A1 (en) * 2023-12-18 2025-06-26 Ideaya Biosciences, Inc. Chemical compounds and uses thereof
WO2026086887A1 (zh) * 2024-10-23 2026-04-30 江苏恒瑞医药股份有限公司 Kat6抑制剂与ar protac的联合

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06500794A (ja) * 1991-03-28 1994-01-27 エーザイ株式会社 複素環式−環式アミン誘導体
US20020028834A1 (en) * 1991-03-28 2002-03-07 Anabella Villalobos Heterocyclic-cyclic amine derivatives
WO2002074746A1 (en) * 2001-03-16 2002-09-26 Yamanouchi Pharmaceutical Co., Ltd. Benzazepine derivatives
JP2006507215A (ja) * 2002-02-22 2006-03-02 バイエル・フアーマシユーチカルズ・コーポレーシヨン 過剰増殖性障害の処置に有用なベンゾフランおよびベンゾチオフェン誘導体
JP2009504690A (ja) * 2005-08-18 2009-02-05 ゲンマブ エー／エス Ｃｄ４結合ペプチドおよび放射線による治療
JP2017508816A (ja) * 2014-03-20 2017-03-30 カペラ セラピューティクス，インコーポレーテッド 癌の治療のためのｅｒｂｂチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体
WO2019243491A1 (en) * 2018-06-20 2019-12-26 Ctxt Pty Limited Compounds
WO2020048548A1 (zh) * 2018-09-07 2020-03-12 正大天晴药业集团股份有限公司 一种作用于crbn蛋白的三并环类化合物
WO2020254946A1 (en) * 2019-06-18 2020-12-24 Pfizer Inc. Benzisoxazole sulfonamide derivatives
WO2020254989A1 (en) * 2019-06-19 2020-12-24 Pfizer Inc. Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105492430B (zh) * 2013-03-15 2017-10-10 基因泰克公司 取代的苯并噁唑及其使用方法
WO2015102929A1 (en) * 2013-12-30 2015-07-09 Novartis Ag Tricyclic sulfonamide derivatives
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
US10787430B2 (en) 2016-06-17 2020-09-29 Fronthera U.S. Pharmaceuticals Llc Hemoglobin modifier compounds and uses thereof
GB201713962D0 (en) 2017-08-31 2017-10-18 Ctxt Pty Ltd Compounds
US11685732B2 (en) 2017-11-29 2023-06-27 Epizyme, Inc. MYST family histone acetyltransferase inhibitors
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
EA202092908A1 (ru) 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. Модуляторы ионных каналов
CN114072394A (zh) 2019-04-25 2022-02-18 拜耳股份公司 用于治疗癌症的酰基磺酰胺

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06500794A (ja) * 1991-03-28 1994-01-27 エーザイ株式会社 複素環式−環式アミン誘導体
US20020028834A1 (en) * 1991-03-28 2002-03-07 Anabella Villalobos Heterocyclic-cyclic amine derivatives
WO2002074746A1 (en) * 2001-03-16 2002-09-26 Yamanouchi Pharmaceutical Co., Ltd. Benzazepine derivatives
JP2006507215A (ja) * 2002-02-22 2006-03-02 バイエル・フアーマシユーチカルズ・コーポレーシヨン 過剰増殖性障害の処置に有用なベンゾフランおよびベンゾチオフェン誘導体
JP2009504690A (ja) * 2005-08-18 2009-02-05 ゲンマブ エー／エス Ｃｄ４結合ペプチドおよび放射線による治療
JP2017508816A (ja) * 2014-03-20 2017-03-30 カペラ セラピューティクス，インコーポレーテッド 癌の治療のためのｅｒｂｂチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体
WO2019243491A1 (en) * 2018-06-20 2019-12-26 Ctxt Pty Limited Compounds
WO2020048548A1 (zh) * 2018-09-07 2020-03-12 正大天晴药业集团股份有限公司 一种作用于crbn蛋白的三并环类化合物
WO2020254946A1 (en) * 2019-06-18 2020-12-24 Pfizer Inc. Benzisoxazole sulfonamide derivatives
WO2020254989A1 (en) * 2019-06-19 2020-12-24 Pfizer Inc. Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives

Also Published As

Publication number Publication date
WO2023016484A1 (zh) 2023-02-16
EP4385989A1 (en) 2024-06-19
AU2022325367A1 (en) 2024-02-08
EP4385989A4 (en) 2024-12-18
CA3228411A1 (en) 2023-02-16
US20250145637A1 (en) 2025-05-08
KR20240046530A (ko) 2024-04-09
TW202321263A (zh) 2023-06-01
MX2024001777A (es) 2024-02-29
CN117597341A (zh) 2024-02-23

Similar Documents

Publication Publication Date Title
EP4385989A1 (en) Sulfonamide derivative, preparation method therefor and medical use thereof
TW202325298A (zh) 含氮的四環化合物、其製備方法及其在醫藥上的應用
JP2024539228A (ja) 含窒素四環式化合物、その調製方法及びその医薬的使用
CN120858101A (zh) 稠合四环类化合物、其制备方法及其在医药上的应用
JP7781059B2 (ja) ピラゾロヘテロアリール系誘導体、その調製方法及びその医薬的応用
JP2024519188A (ja) 含窒素複素環系化合物、その調製方法及びその医薬的応用
CN114149423B (zh) 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用
EP4349831A1 (en) Quinolinamine compound, preparation method therefor and application thereof in pharmaceuticals
CN120230123A (zh) 稠环类化合物、其制备方法及其在医药上的应用
TW201934554A (zh) 吡唑并[1,5-a][1,3,5]三<img align="absmiddle" height="18px" width="27px" file="d10999.TIF" alt="其他非圖式 d10999.TIF" img-content="tif" orientation="portrait" inline="yes"></img>-2-胺類衍生物、其製備方法及其在醫藥上的應用
TW202102505A (zh) 吡咯并雜環類衍生物、其製備方法及其在醫藥上的應用
CN115594695A (zh) 大环类化合物、其制备方法及其在医药上的应用
JP2024532512A (ja) Ｔｙｋ２／ｊａｋ１シュードキナーゼドメイン阻害剤としての化合物ならびに合成および使用方法
CN111320633B (zh) 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途
CN107880038A (zh) [1,2,4]三唑并[1,5‑a]吡啶类化合物及其制备方法和医药用途
CN112996783A (zh) 2-氨基嘧啶类衍生物、其制备方法及其在医药上的应用
CN116829556A (zh) 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用
EP3683206A1 (en) Deuterium atom-substituted indole formamide derivative, preparation method therefor, and medical applications thereof
AU2024319888A1 (en) Heteroaryl compound, preparation method therefor, and use thereof in medicine
CN115611877A (zh) 磺酰胺类化合物、其制备方法及其在医药上的应用
CN115867552B (zh) 咪唑并嘧啶类衍生物、其制备方法及其在医药上的应用
JP2023536442A (ja) オキサアザスピロ環系誘導体、その調製方法及びその医薬的応用
EA053325B1 (ru) Сульфонамидное производное, способ его получения и его применение в медицине
CA3300208A1 (en) Heteroaryl compound, preparation method therefor, and use thereof in medicine
CA3300933A1 (en) Sulfonamide compound, and preparation method therefor and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250808

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260414

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260424